Literature DB >> 9004253

Endothelin-1 induces GM-CSF, IL-6 and IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B).

J Mullol1, J N Baraniuk, C Logun, T Benfield, C Picado, J H Shelhamer.   

Abstract

Endothelin (ET) is a powerful vasoconstrictor and bronchoconstrictor peptide that may be involved in the pathogenesis of bronchial asthma. We have investigated the effect of ET on the secretion of IL-6, IL-8, GM-CSF and G-CSF in a bronchial epithelial cell line (BEAS-2B). Incubation of BEAS-2B cells with ET-1 (10(-13) to 10(-7) M) for 4 h caused dose-related increases in the release of IL-8 (68% increase above control, P < 0.001) and IL-6 (43% increase above control, P < 0.001), compared to untreated control cells. After 48 h incubation, ET-1 also increased the release of IL-8 by 35% (P < 0.001) and GM-CSF by 38% (P < 0.01). ET-1 had no significant effect on G-CSF release. ET-1 did not induce cell proliferation at 24 or 48 h. Since ET-immunoreactive materials are expressed in epithelial cells in asthma, it is possible that ET-1 of epithelial origin may act in a paracrine or autocrine fashion on airway epithelial ET receptors to stimulate IL-8, IL-N6 and GM-CSF release. Thus, ET-1 may play a role in the regulation of the cytokine responses involved in inflammation of the airway mucosa.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9004253     DOI: 10.1016/s0143-4179(96)90038-4

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  11 in total

Review 1.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

2.  Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.

Authors:  M Roland; A Bhowmik; R J Sapsford; T A Seemungal; D J Jeffries; T D Warner; J A Wedzicha
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

3.  Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

Authors:  Yong Soo Kwon; Su Young Chi; Hong Joon Shin; Eun Young Kim; Byeong Kab Yoon; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Young Chul Kim; Sung Chul Lim
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

4.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

5.  Sputum endothelin-1 level is associated with active pulmonary tuberculosis and effectiveness of anti-tuberculosis chemotherapy.

Authors:  Xiang Wang; Jingqun Tang; Ranran Wang; Chen Chen; Shichuan Tan; Fenglei Yu; Yongguang Tao; Yunping Li
Journal:  Exp Ther Med       Date:  2016-01-11       Impact factor: 2.447

Review 6.  Current Pharmacological Approach to ARDS: The Place of Bosentan.

Authors:  Omer Araz
Journal:  Eurasian J Med       Date:  2020-02

7.  Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1.

Authors:  Amy M Sutcliffe; Deborah L Clarke; Dawn A Bradbury; Lisa M Corbett; Jamie A Patel; Alan J Knox
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

8.  Lung function decline is associated with serum uric acid in Korean health screening individuals.

Authors:  Kyung-Min Ahn; Suh-Young Lee; So-Hee Lee; Sun-Sin Kim; Heung-Woo Park
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

9.  Effects of bile acids on human airway epithelial cells: implications for aerodigestive diseases.

Authors:  Adil Aldhahrani; Bernard Verdon; Chris Ward; Jeffery Pearson
Journal:  ERJ Open Res       Date:  2017-03-22

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.